A prescription for applying the method of molecular similarity calculations based on electrostatic potentials and fields is developed by consideration of a typical structure-activity series. Firm conclusions are drawn about the nature of the grid of points surrounding the molecules and about the choice of geometry, but options for point charges are less clearcut.
Invasive infections caused by Candida krusei are a significant concern because this organism is intrinsically resistant to fluconazole. Voriconazole is more active than fluconazole against C. krusei in vitro. One mechanism of fluconazole resistance in C. krusei is diminished sensitivity of the target enzyme, cytochrome P450 sterol 14␣-demethylase (CYP51), to inhibition by this drug. We investigated the interactions of fluconazole and voriconazole with the CYP51s of C. krusei (ckCYP51) and fluconazole-susceptible Candida albicans (caCYP51). We found that voriconazole was a more potent inhibitor of both ckCYP51 and caCYP51 in cell extracts than was fluconazole. Also, the ckCYP51 was less sensitive to inhibition by both drugs than was caCYP51. These results were confirmed by expressing the CYP51 genes from C. krusei and C. albicans in Saccharomyces cerevisiae and determining the susceptibility of the transformants to voriconazole and fluconazole. We constructed homology models of the CYP51s of C. albicans and C. krusei based on the crystal structure of CYP51 from Mycobacterium tuberculosis. These models predicted that voriconazole is a more potent inhibitor of both caCYP51 and ckCYP51 than is fluconazole, because the extra methyl group of voriconazole results in a stronger hydrophobic interaction with the aromatic amino acids in the substrate binding site and more extensive filling of this site. Although there are multiple differences in the predicted amino acid sequence of caCYP51 and ckCYP51, the models of the two enzymes were quite similar and the mechanism for the relative resistance of ckCYP51 to the azoles was not apparent.Candida krusei is an opportunistic pathogen that can cause serious infections in immunocompromised patients (1, 6, 7). This organism is intrinsically resistant to fluconazole. The new triazole voriconazole has greater in vitro activity than fluconazole against C. krusei (5, 15). Two mechanisms of azole resistance in C. krusei have been described. Isolates of C. krusei that are resistant to itraconazole exhibit reduced drug accumulation, suggesting that resistance to this drug is due to the activity of one or more drug efflux pumps (29). Recently, two ATP binding cassette transporters have been identified in C. krusei. Increased expression of these transporters is associated with reduced susceptibility to miconazole (9).A second mechanism of azole resistance in C. krusei is diminished sensitivity of the target enzyme, cytochrome P450 sterol 14␣-demethylase (CYP51), to inhibition by an azole antifungal agent. We have determined previously that fluconazole resistance in some strains of C. krusei is mediated predominantly by this mechanism (17).In the present study, we cloned the full-length C. krusei CYP51 and examined its contribution to the differential sensitivity of C. krusei to fluconazole and voriconazole. We also used computer-assisted molecular modeling to examine the interactions of fluconazole and voriconazole with the predicted Candida albicans and C. krusei CYP51s. MATERIALS AND ME...
Human immunodeficiency virus type 1 (HIV-1) integrase is one of three virally encoded enzymes essential for replication and, therefore, a rational choice as a drug target for the treatment of HIV-1 infected individuals. In 2007 raltegravir became the first integrase inhibitor approved for use in the treatment of HIV infected patients, more than a decade since the approval of the first protease inhibitor (saquinavir, Hoffman La-Roche, 1995) and two decades since the approval of the first reverse transcriptase inhibitor (retrovir, Glaxo Smithkline, 1987). The slow progress towards a clinically effective HIV-1 integrase inhibitor can at least in part be attributed to a poor structural understanding of this key viral protein. Here we describe the development of a restrained molecular dynamics protocol that produces a more accurate model of the active site of this drug target. This model provides an advance on previously described models as it ensures that the catalytic DDE motif makes correct, monodentate, interactions with the two active site magnesium ions. Dynamic restraints applied to this coordination state create models with the correct solvation sphere for the metal ion complex and highlight the coordination sites available for metal binding ligands. Applying appropriate dynamic flexibility to the core domain allowed the inclusion of multiple conformational states in subsequent docking studies. These models have allowed us to (1) explore the effects of key drug resistance mutations on the dynamic flexibility and conformational preferences of HIV integrase and to (2) study raltegravir binding in the context of these dynamic models of both wild type and the G140S/Q148H drug resistant enzyme.
A method of comparing molecules on a quantitative basis which includes the possibility of compounds using thei r flexibility to achieve matching is described and applied to a series of hypoglycemic and hypolipidemic agents.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.